Kezar Life Sciences is advancing two drug development programs targeting distinct, fundamental aspects of cellular physiology dealing with protein homeostasis. Protein degradation, which in cells of the immune system is regulated by the immunoproteasome, and protein secretion, which is regulated by the Sec61 translocon on the endoplasmic reticulum. Kezar’s first drug candidate, KZR-616, a selective inhibitor of the immunoproteasome, entered clinical trials in 2016.
Kezar Life Sciences
